The Scientific Update Team had a brilliant evening having dinner and listening to the Jazz on The Pantiles in Royal Tunbridge Wells.  To be together celebrating that we are still very much here and have survived the most challenging 18 months in our history, was really rather special. We can’t wait to see you all

The scheme below shows the synthesis of a late-stage intermediate towards PF-06826647, a compound identified by Pfizer as a potent and selective tyrosine kinase 2 (TYK-2) inhibitor that has entered phase 2 clinical trials for the treatment of autoimmune diseases. Can you identify intermediates A, B and D? Answers and a reference will be posted

Last month I posted a scheme for the synthesis of a late-stage intermediate towards AZD9833, a compound identified by AstraZeneca as a selective estrogen receptor degrader (SERD) and antagonist that is currently in phase 2b clinical trials for the treatment of ER+ breast cancer. I asked if you could identify reagents or intermediates A-C. Below are